Intervention

enzalutamide

ClinicalTrials.gov intervention label

Clinical trials28
Recruiting4
Common conditions21
Lead sponsors shown15

Clinical trials

28 shown
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerNCT07198633 · 2025-11-05
RECRUITING
Enzalutamide Implants (Enolen) in Patients With Prostate CancerNCT06257693 · 2024-06-21
RECRUITING
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerNCT06702995 · 2023-04-19
RECRUITING
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerNCT04729114 · 2021-06-14
RECRUITING
A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerNCT07783282 · 2026-08-31
NOT_YET_RECRUITING
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate CancerNCT07104110 · 2025-10-01
NOT_YET_RECRUITING
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007 · 2023-02-13
COMPLETED
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsNCT05457257 · 2022-07-29
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate CancerNCT04094519 · 2020-01-27
COMPLETED
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsNCT04052204 · 2019-12-30
TERMINATED
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentNCT03531827 · 2019-03-26
TERMINATED
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerNCT03338790 · 2017-12-19
COMPLETED
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in SwedenNCT03328364 · 2017-12-01
COMPLETED
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)NCT02987543 · 2017-02-06
COMPLETED
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022 · 2016-12-22
ACTIVE_NOT_RECRUITING
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentNCT02485691 · 2015-11-09
COMPLETED
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT02495974 · 2015-09-08
COMPLETED
Long-Term Specified Drug Use-Results Survey for Xtandi CapsuleNCT02669771 · 2014-11-30
COMPLETED
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerNCT01990196 · 2014-09-23
ACTIVE_NOT_RECRUITING
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate CancerNCT02058706 · 2014-05-01
COMPLETED
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)NCT02057939 · 2014-04-01
COMPLETED
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate CancerNCT01949337 · 2014-01-22
UNKNOWN
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate CancerNCT02012296 · 2013-12-13
COMPLETED
Enzalutamide in Patients With High-risk Prostate CancerNCT01927627 · 2013-11-11
COMPLETED
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerNCT01981122 · 2013-09-01
COMPLETED
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsNCT01650194 · 2012-07-09
COMPLETED
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerNCT01597193 · 2012-04-30
COMPLETED
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerNCT01288911 · 2011-03-22
COMPLETED

Common conditions

Prostate Cancer7Metastatic Castration Resistant Prostate Cancer4Adenocarcinoma of the Prostate3Metastatic Castration-resistant Prostate Cancer3Recurrent Prostate Cancer3Stage IV Prostate Cancer3Hormone-resistant Prostate Cancer2Metastatic Castration Resistant Prostate Cancer (mCRPC)2Prostatic Neoplasms2Advanced Prostate Cancer1Breast Cancer1Castration-resistant Prostate Cancer1mCRPC (Metastatic Castration-resistant Prostate Cancer)1Metastatic Castrate-Resistant Prostate Cancer1Metastatic Castration Sensitive Prostate Cancer (mCSPC)1Metastatic Castration-sensitive Prostate Cancer1Metastatic Prostate Cancer1Prostate Adenocarcinoma1Prostate Cancer Metastatic1Prostate Neoplasms1Squamous Cell Carcinoma of the Head and Neck (SCCHN)1

Trial status mix

COMPLETED16
RECRUITING4
ACTIVE_NOT_RECRUITING3
NOT_YET_RECRUITING2
TERMINATED2
UNKNOWN1

Phase mix

PHASE215
PHASE110
PHASE32
PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.